| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2022 | 745.13% | Morgan Stanley | $32 → $20 | Maintains | Overweight |
| 01/10/2022 | 1421.23% | HC Wainwright & Co. | → $36 | Initiates Coverage On | → Buy |
| 11/16/2021 | 1209.95% | Raymond James | → $31 | Initiates Coverage On | → Outperform |
| 11/16/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 11/16/2021 | 1252.21% | Morgan Stanley | → $32 | Initiates Coverage On | → Overweight |
Xilio Therapeutics Questions & Answers
The latest price target for Xilio Therapeutics (NASDAQ: XLO) was reported by Morgan Stanley on August 10, 2022. The analyst firm set a price target for $20.00 expecting XLO to rise to within 12 months (a possible 745.13% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Xilio Therapeutics (NASDAQ: XLO) was provided by Morgan Stanley, and Xilio Therapeutics maintained their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xilio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xilio Therapeutics was filed on August 10, 2022 so you should expect the next rating to be made available sometime around August 10, 2023.
While ratings are subjective and will change, the latest Xilio Therapeutics (XLO) rating was a maintained with a price target of $32.00 to $20.00. The current price Xilio Therapeutics (XLO) is trading at is $2.37, which is out of the analyst's predicted range.